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Chromosome instability (CIN) is associatedwith poor
survival and therapeutic outcome in a number of ma-
lignancies. Despite this correlation, CIN can also lead
to growth disadvantages. Here, we show that simul-
taneous overexpression of the mitotic checkpoint
protein Mad2 with KrasG12D or Her2 in mammary
glands of adult mice results in mitotic checkpoint
overactivation and a delay in tumor onset. Time-
lapse imaging of organotypic cultures and patho-
logic analysis prior to tumor establishment reveals
error-prone mitosis, mitotic arrest, and cell death.
Nonetheless, Mad2 expression persists and in-
creases karyotype complexity in Kras tumors. Faced
with the selective pressure of oncogene withdrawal,
Mad2-positive tumors have a higher frequency of
developing persistent subclones that avoid remis-
sion and continue to grow.INTRODUCTION
Genomic instability is one of the main enabling features of can-
cer, setting the path for subsequent events of uncontrolled
growth, invasion, metastasis, and drug resistance (Hanahan
and Weinberg, 2011). One of the most studied mechanisms of
generating genomic variability is aberrant distribution of chromo-
somes during cell division, known as chromosomal instability
(CIN) (Boveri, 1912). Large-scale analyses of human tumors pre-
dict that 86% of solid and 72% of hematopoietic malignancies
are aneuploid (Zasadil et al., 2013). CIN gene signatures have
become an important prognostic tool to evaluate patient survival
and therapeutic outcome (Carter et al., 2006; Habermann et al.,
2009). However, deregulation of CIN genes in vitro causes a
decrease in cellular fitness through p53-mediated cell death
and metabolic stress because of protein imbalance (Li et al.,
2010; Thompson and Compton, 2010; Torres et al., 2007).
Studies in vivo show that CIN genes can have either no effect
or lead to an increase in spontaneous or carcinogen-inducedCel
This is an open access article under the CC BY-Ntumorigenesis (Schvartzman et al., 2010). In combination with
loss of known tumor suppressor genes or oncogene activation,
even suppressive effects on tumor induction have been reported
(Janssen and Medema, 2013; Zasadil et al., 2013). To explain
these ambiguities, Silk et al. (2013) proposed a model in which
the level of CIN might tip the balance between tumor-promoting
and -suppressive outcomes. Despite this, it is still unclear when
during tumor development aneuploidy exerts its modulating ef-
fects on tumor growth.
Most researchers agree that oncogenes are themain drivers of
tumorigenesis, whereas CIN contributes to genetic variation and
plasticity (Chen et al., 2012; Tamborero et al., 2013). To under-
stand how genetic instability can influence classical oncogen-
esis, we focused on the effect of Mad2-induced CIN during
oncogene-driven tumorigenesis. Mad2 is a downstream target
of two major tumor suppressors: RB and p53 (Schvartzman
et al., 2011). In addition, Mad2 overexpression in a transgenic
model of KrasG12D-driven lung carcinogenesis facilitated both
tumor onset and relapse following oncogene silencing (Sotillo
et al., 2010). Moreover, its elevated level in various cancer types
(Rhodes et al., 2004) makes it an attractive target for cancer
studies. Considering the detrimental effect of aneuploidy on
cellular homeostasis (Torres et al., 2007) and the continued
controversy with respect to both its tumor-promoting and tu-
mor-suppressing function in vivo, it is unclear whether this
synergy is a general principle of cancer.
Breast cancer is the most common malignancy in women
worldwide and can be driven by a wide spectrum of oncogenes
(Sanchez-Garcia et al., 2014; Stephens et al., 2012). Although
Kras mutations are prevalent in 30% of all human cancers,
Her2 is deregulated in 15% of human mammary tumors (Cerami
et al., 2012; Gao et al., 2013). Similar to lung cancer, human
breast tumors are highly aneuploid (Zasadil et al., 2013); how-
ever, animal models are less prone to CIN-induced mammary
tumorigenesis (Duijf and Benezra, 2013).
We combined KrasG12D or Her2 conditional mouse models
withMad2 overexpression in the adult mammary gland to mirror
the timing of tumor onset in breast cancer patients. This resulted
in a strong delay in tumor formation compared with KrasG12D or
Her2 expression alone. Pathologic analysis of early events after
transgene induction revealed increased cell turnover caused byl Reports 15, 2679–2691, June 21, 2016 ª 2016 The Authors. 2679
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Mad2 Overexpression Delays Kras-Driven Tumor Initiation and Leads to Phenotypic Variance
(A) Tumor-free survival after doxycycline administration. (control, n = 33;Mad2, n = 33; KrasG12D, n = 107; KrasG12D/Mad2, n = 75), Mantel-Cox test, p < 0.0001.
(B) Tumors per animal. Mann-Whitney test, p = 0.0062.
(C) Mammary glands after 4, 30, and 100 days on doxycycline stained against HA-Mad2. Scale bar, 50 mm.
(D) Quantification of HA-positive cells per acinus after 4 and 100 days on doxycycline (M, n = 7; KM-A, n = 7; KM-B, n = 6; KM-C, n = 5).
(E) Tumor onset in K andKM subgroups (K, n = 95; KM-A, n = 14; KM-B, n = 10; KM-C, n = 7). Kruskal-Wallis test, p < 0.0001; Dunn’smultiple comparisons test. ns,
not significant.
**p < 0.01, ****p < 0.0001. See also Figure S1.an initial depletion of Mad2-expressing cells and an accu-
mulation of mitotic errors in the surviving population. Three
phenotypic subgroups of the Kras/Mad2-expressing cohort
were identified, all of which resulted in the generation of Mad2-
overexpressing, highly aneuploid tumors. The level of aneuploidy
seen in Her2 tumors was not exceeded by additional Mad2
expression, indicating that tumors self-regulate the ultimate level
of CIN (Montagna et al., 2002). In both oncogenic models, Mad2-
inducedCIN failed to have an effect on tumor progression but led
to the generation of abnormal cells that survived the strong
selective pressure of oncogene withdrawal.
RESULTS
Mad2 Overexpression Delays Tumor Onset in
Kras-Driven Breast Cancer
To better understand the effect of CIN on tumor initiation
we generated a mouse mammary tumor virus (MMTV)-driven,
doxycycline-inducible model to overexpress hemagglutinin2680 Cell Reports 15, 2679–2691, June 21, 2016(HA)-tagged Mad2 (Sotillo et al., 2007) and KrasG12D (Fisher
et al., 2001) in mammary glands of adult virgin mice (Gunther
et al., 2002). Mice were placed on a doxycycline-enriched diet
and followed weekly for tumor development. Monitored mice
were divided into four cohorts depending on the presence of
KrasG12D (K),Mad2 (M), both KrasG12D andMad2 (KM), and con-
trol mice lacking transgene expression (CTRL).
CTRL and M animals developed no tumors during the aging
period of 18 months, suggesting that elevated levels of Mad2
are not sufficient to induce breast cancer in this model (Fig-
ure 1A). As described previously, expression of KrasG12D in the
mammary gland results in the development of breast tumors
(Podsypanina et al., 2008; Figure 1A). Simultaneous overexpres-
sion of KrasG12D andMad2 led to a significant delay in mammary
tumor onset compared with KrasG12D alone. Although K mice
showed palpable nodules after a median latency of 147 days
(n = 107), KM mice survived 221 days (n = 75) without tumors
(Figure 1A). In addition, KM mice developed a lower number of
tumors per animal compared with K mice (Figure 1B). These
findings show that elevatedMad2 levels are detrimental to onco-
gene-driven mammary tumor initiation.
Sequential Pathological Analysis Reveals Phenotypic
Subtypes in KrasG12D/Mad2 Animals
To address the consequences of high Mad2 levels on early
events during tumorigenesis, we evaluated the histological
changes in mammary glands stained with an HA-specific anti-
body (to detect exogenous HA-tagged Mad2; Figure 1C) and
Kras (Figure S1A) prior to formation of palpable tumors. Serial
surgeries on different mammary glands of the same animal
were performed after 4, 30, and 100 days of transgene induction.
In this 3-month period, young wild-type animals showed no sig-
nificant changes in tissue architecture (Figures 1C; Figure S1A)
except estrous cycle-dependent fluctuations in proliferation
and apoptosis (Fata et al., 2001). To control for these hormonal
influences on tissue remodeling, all surgeries were performed
at the pro-estrous stage.
Overexpression of KrasG12D in the mammary gland led to
gradual neoplastic growth starting with a numerical expansion
of acinar density 30 days post-induction. The increase in epithe-
lial cells resulted in the formation of micro-nodules that, by
100 days, had already expanded into palpable tumors
(Figure S1A).
Upon Mad2 overexpression, an initial enlargement of ducts
and a predominant localization of Mad2-positive mitotic cells in-
side the acinar lumen were observed. The decreased number of
Mad2-expressing cells and the return to normal tissue architec-
ture at 100 days suggested epithelial cell clearance during early
days of transgene induction (Figures 1C and 1D; Figures S1A–
S1C). These observations are in line with the lack of carcinogenic
growth seen in Mad2-overexpressing animals.
Morphological examinations of the KM cohort prompted us to
partition it into three phenotypic subgroups. All animals started
with a normal distribution of Mad2-expressing cells per acinus
(average of 38.8% of HA-positive cells at 4 days of induction)
but differed both in the Kras levels and in the expression pattern
of Mad2 after 100 days on doxycycline (Figures 1C and 1D; Fig-
ures S1B–S1E). Group A continuously expressed very low
amounts of Kras compared with Mad2 and, similar to the M
cohort, reduced Mad2-expressing cells during the first
100 days on doxycycline. After a strong initial luminal filling of
mitotic cells at 4 days, the ductal system regressed to a normal
mammary architecture. Groups B and C displayed higher levels
of Kras and were prone to acinar hyperplasia at 4 days. After
the expansion period, mammary glands underwent a regression
phase leading to an almost complete reconstitution of the normal
state after 30 days on doxycycline. After 3months, themammary
glands of Group B showed increased budding and branching
from themain ducts, an augmented number of Mad2-expressing
cells, and a slight increase in Kras levels. Group C showed no
change in the overall percentage of Mad2-expressing cells,
whereas total expression levels were reduced and Kras expres-
sion substantially augmented (Figures 1C and 1D; Figures S1B–
S1E). Phenotypically, groupCwas reminiscent of the tumorigenic
progression observed in the KrasG12D-driven model and had an
equally early tumor onset at 165 days after doxycycline adminis-
tration, whereas group B developed the first palpable tumors at233 days and group A at 313 days (Figure 1E). Together, these
data best fit a model in which high levels of Mad2 have a detri-
mental effect on mitotic progression, leading to cell depletion.
Only in thepresenceof sufficient amounts of Kras can this pheno-
type be overcome. During transgene induction, the epithelial cell
population can undergo different selective scenarios leading to
loss of Mad2-expressing cells in the presence of low Kras levels,
tolerance of high Mad2 levels in the presence of high Kras levels,
or early selection of cells with lower Mad2 levels.
High Levels of Mad2 Induce Mitotic Arrest and Trigger
Epithelial Cell Turnover
To understand the morphogenetic processes caused by Mad2
overexpression during early pre-malignancy, we examined
epithelial cell turnover in vivo via quantification of phospho-His-
tone 3 (pH3) and terminal deoxynucleotidyl transferase-medi-
ated d-UTP nick end labeling (TUNEL). Compared with controls,
K mice showed an incremented number of pH3-positive cells
with a punctate staining pattern at 4 days, hinting at elevated
proliferation (Figures 2A and 2C). In M and KMmice, an increase
was also observed, but the staining clearly exhibitedmorpholog-
ical features of mitosis. Notably, the majority of pH3-positive
cells in the M and KM cohorts were located inside the acinar
lumen, suggesting delamination of mitotic cells (Figure 2A). In
addition, elevated numbers of TUNEL-positive cells were found
in M and KM groups compared with K and CTRL cohorts
4 days after transgene induction (Figures 2B and 2D; Figure S2A)
and were clearly associated with Mad2 expression (Figure S2B).
Together, these results suggest that high Mad2 levels in mam-
mary epithelial cells in vivo may lead to mitotic arrest followed
by apical extrusion and cell death. However, the presence of
Mad2-positive cells in all KM subgroups at 100 days indicated
that a substantial number of cells must have escaped mitotic
block and apoptosis.
One mechanism to escape mitotic arrest is to progress
through mitosis without cytokinesis, otherwise known as mitotic
slippage. To evaluate this possibility and its effect on chromo-
some content, we measured the nuclear size of mammary
epithelial cells after 4 and 100 days of transgene expression.
Numerical aberrations in the karyotype have been reported to
correlate directly with nuclear size (Pe´rez de Castro et al.,
2013). Mammary cells in KM animals acquired a higher variance
of nuclear size compared with K and CTRL mice. KM group A
showed no significant changes in nuclear volume. Group B
reached the highest nuclear volume on day 4, together with
increased cell death (Figures S2A, S2C, and S2D), returning to
a less pronounced phenotype after 100 days of induction (Fig-
ure 2E). Together with the development of the first tumor-like
nodules, KM group C doubled their nuclear volume at
100 days (Figure 2E). These results suggest that a fraction of
cells escape the block imposed by Mad2 overexpression and
accumulate errors during chromosome segregation.
Mad2-Induced Mitotic Arrest Leads to Cell
Delamination, Spindle Defects, and Increased Cell
Death
In vivo analysis of mammary glands following doxycycline
administration indicated an increased mitotic index and aCell Reports 15, 2679–2691, June 21, 2016 2681
Figure 2. Mad2 Overexpression Increases Epithelial Cell Turnover after 4 Days of Transgene Induction In Vivo
(A) Phospho-histone 3 staining of mammary glands after 4 days on doxycycline. Scale bar, 50 mm.
(B) Double immunofluorescence of TUNEL (red) and HA-Mad2 (green) on mammary glands after 4 days on doxycycline (DAPI, blue). Scale bar, 50 mm.
(C andD) Quantification of pH3 (C; CTRL, n = 6; M, n = 5; K, n = 6; KM, n = 13) and TUNEL-positive cells (D; CTRL, n = 6; M, n = 6; K, n = 9; KM, n = 14) per acinus at
4 days on doxycycline. Points represent single acinar measurements.
(E) Nuclear volume quantification relative to control cells at 100days on doxycycline (CTRL, n = 6; M, n = 5; K, n = 5; KM-A, n = 6; KM-B, n = 5; KM-C, n = 4). Points
represent single nuclear measurements; F-test for size variability.
Data were analyzed by Kruskal-Wallis test, p < 0.0001; Dunn’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2.possible variance in the genomic content because of Mad2 over-
expression. To better understand whether the mitotic arrest
induced by high Mad2 was responsible for cell depletion, we
used a 3D culture system of primary mammary epithelial cells.
3D culture offers the possibility of recapitulating the growth of
mammary acini ex vivo and allows the visualization of epithelial
tissues in a microscopically accessible context (Jechlinger
et al., 2009).
Both control samples and KrasG12D-expressing cultures
showed no evident morphological changes after 36 hr on doxy-
cycline (Figures 3A and 3B; Figure S3A). Mad2 overexpression
(in both ColA1-Mad2 and TetO-Mad2 strains; Figures S3B and
S3C) led to a dramatic increase in the number of mitotic cells
that mostly appeared in the acinar lumen starting 30 hr post-in-
duction. This phenotype was exacerbated in the combination of2682 Cell Reports 15, 2679–2691, June 21, 2016Mad2 overexpression and mutant Kras, where the acinar struc-
tures were filled with mitotic cells and cell fragments (Figures 3A
and 3B; Figure S3A). In line with previous findings, the observed
phenotype is likely due to mitotic arrest as a consequence of
checkpoint overactivation, given that Mad2 overexpression re-
sults in an accumulation of Cyclin B (Figures S3D and S3E)
and downregulation of Aurora B (Figures S3F and S3G; Kabeche
and Compton, 2012; Sotillo et al., 2007). To investigate whether
the arrest was followed by apoptosis, 3D cultures were stained
for cleaved Caspase 3 after 36 hr on doxycycline. K structures
did not exceed the cell turnover seen in control cultures. How-
ever, M and KM spheres contained a significantly elevated num-
ber of apoptotic cells per acinus (Figures 3A and 3C). Nuclear
volume counts after 4 days on doxycycline indicated that a sig-
nificant number of M and KM cells became polyploid (Figure 3D).
Figure 3. 3D Cultures Recapitulate Increased Proliferation and Apoptosis following Mad2 Induction
(A) Representative immunofluorescence images on fixed mammary spheroid cultures after 36 hr on doxycycline. Scale bars, 25 mm.
(B and C) Quantification of mitotic cells (B; CTRL, n = 7; M, n = 4; K, n = 5; KM, n = 4) and cleaved Caspase 3-positive (C) cells per acinus after 36 hr on doxycycline
(CTRL, n = 9; M, n = 6; K, n = 5; KM, n = 4).
(D) Nuclear volume quantification in spheroids relative to control cells after 4 days on doxycycline (CTRL, n = 8; M, n = 4; K, n = 3; KM, n = 4). Points represent
single nuclear measurements.
Data were analyzed by Kruskal-Wallis test, p < 0.0001; Dunn’s multiple comparisons test. ColA1-HA-Mad2 animals were used: 2 in M and 2 in KM. ****p < 0.0001.
See also Figure S3.Taken together, the 3D culture system recapitulated the pheno-
types seen in vivo.
Taking advantage of time-lapse imaging, we monitored the
fate of single cells expressing Histone2B-GFP in acinar spheres
after administration of doxycycline for 30 hr. Mitotic cell division
in control cultures as well as in Kras-expressing spheroids is ori-
ented perpendicularly to the apical and basal membrane within
the epithelial layer and is completed within 1–2 hr (Figures 4A
and 4C; Figure S4A; Movies S1 and S2). However, in M and
KM cultures, mitosis was initiated inside the epithelial layer,
but cells arrested at metaphase for over 8 hr in 100% of the
cycling cells in M and 91% in KM (Figures 4A and 4C). This pro-
longed mitotic block led to stepwise delamination until, in some
cases, contact with neighboring cells was completely lost. After-
ward, cells were either degraded into apoptotic blebs (85% in Mand 79% in KM; Figures 4A, center, and 4D) or completed cell
division inside the epithelial rim (15% in M and 12% in KM; Fig-
ures 4A, bottom, and 4D).
In 43%ofMad2 dividing cells and 33.7%of KM,mitotic abnor-
malities, including chromosome misalignments, lagging chro-
mosomes, and micronuclei formation, were observed (Figures
4B and 4E; Figures S4B–S4D; Movies S3, S4, and S5). These
aberrations are likely causes for consequent aneuploidization
(Figure 4F) and/or the depletion of Mad2-expressing cells.
Mad2 Overexpression Increases Chromosome
Missegregation Rates in KrasG12D-Positive Mammary
Tumors
Deregulation ofmitotic checkpoint genes in vivo has been shown
to increase mitotic errors and is strongly associated with a CINCell Reports 15, 2679–2691, June 21, 2016 2683
Figure 4. Time-Lapse Imaging of Organotypic Cultures Reveals Error-Prone Mitosis because of Elevated Mad2 Levels
(A) Time-lapse micrography of control and KrasG12D/Mad2 spheroids in vitro; t = 0 after 30 hr on doxycycline. The yellow circle indicates mitotic cells (H2B-GFP,
green). Scale bar, 25 mm. Top: control cell entering mitosis and completing cell division inside the epithelial rim. Center: a KM cell arrests in mitosis, displays
misaligned chromosomes, falls into the lumen, and dies after 11 hr. Bottom: KM cell arrests in mitosis, initiates apical extrusion, but reintegrates into the
epithelial rim.
(B) Representative 3D reconstructions of a KM mitotic cell with misaligned chromosomes.
(C) Duration of mitosis in spheroid cultures (CTRL, 30 cells; K, 7 cells; M, 54 cells; KM, 42 cells); Kruskal-Wallis test, p < 0.0001; Dunn’s multiple comparisons test.
(D) Fate of mitotic cells during 20-hr time-lapse in vitro (CTRL, 30 cells; K, 7 cells; M, 54 cells; KM, 42 cells).
(E) Percentage of mitotic errors per acinus (CTRL, 29 cells; K, 7 cells; M, 45 cells; KM, 35 cells); one-way ANOVA test, p < 0.0001; Holm Sidak’s multiple
comparisons test.
(F) Outcome of completed cell division after mitotic arrest in Mad2-expressing acini.
CTRL, n = 4; K, n = 3;M, n (ColA1-Mad2) = 2 and n (TetO-Mad2) = 1; KM, n (ColA1-Mad2) = 3 and n (TetO-Mad2) = 2. ****p < 0.0001. See also Figure S4 andMovies
S1, S2, S3, S4, and S5.phenotype in human tumors (Janssen and Medema, 2013).
DespiteMad2’s initial detrimental effects, analysis of tumor sam-
ples from all three KM subgroups verified the presence of both
transgenes (Figures S5A and S5B), and immunohistochemistry
for HA revealed Mad2-expressing cells in all tumors analyzed
(Figure S5C). Nuclear size measurements proved a higher vari-
ance and a significant gain in nuclear volume in KM tumor cells
compared with K (Figures S5D and S5E). In line with the finding
of Kras inducing centrosome abnormalities (Zeng et al., 2010),
K tumors also showed an increase in nuclear variance over con-
trol mice (Figure S5E). To determine the full extent of Mad2’s
effects on karyotype composition and chromosome rearrange-2684 Cell Reports 15, 2679–2691, June 21, 2016ments, we performed low-pass, whole-genome sequencing of
primary tumors (median coverage 0.11-fold), followed by
somatic copy number alteration (SCNA) analysis. On average,
genomes of KM tumors were more frequently affected by and
had significantly more SCNAs than K tumors (mean 2.70 versus
0.85; Figures 5A and 5B). The most frequent variant types pre-
sent in either cohort were whole chromosome gains and losses,
followed by large partial chromosome gains and losses (Fig-
ure 5A). Although chromosomes 2 and 4 were recurrently
affected in both cohorts (30% and 25% in K tumors as well as
34.7% and 52% in KM tumors, respectively), additional aneu-
ploidies were present in nearly all other chromosomes of KM
Figure 5. Mad2 Overexpression Boosts Aneuploidy and Facilitates Tumor Persistence after Oncogene Withdrawal
(A) SCNAs in 20 Kras and 23 Kras/Mad2 primary tumors. Shown are whole chromosome gain (WCG) and loss (WCL), partial chromosome gain (PCG) and loss
(PCL), focal amplification (AMP), and gross chromosomal rearrangement (GCR, red). x Axis, individual tumors; y axis, SCNAs per tumor.
(B) Average SCNAs in K and KM tumors; Fisher’s exact test, p = 0.01039.
(C) Representative micrographs of KM tumor cells in vitro (H2B-GFP, green). Scale bar, 25 mm. Top: furrow regression and polyploidization. Bottom: lagging
chromosome during anaphase and cytokinesis failure.
(D) Percentage of mitotic errors per tumor (K, n = 4, 74 cells; KM, n = 5, 84 cells); Mann-Whitney test, p = 0.0317.
(E) Representative examples of tumor development in K and KM tumors. The arrow indicates doxycycline withdrawal (day 0).
(F) Status of tumor regression in K and KM cohorts 2 months after doxycycline withdrawal.
*p < 0.05. See also Figures S5 and S6.tumors (Figure S5F). No specific SCNAs were found to occur at a
significantly higher frequency in KM versus K tumors, suggesting
that, in this model, Mad2 serves to increase the total amount of
aneuploidy in the tumor rather than selecting for specific rear-
rangement patterns.
To analyze whetherMad2 influences CIN during tumor growth,
we performed time-lapse microscopy of primary tumor cells.
Indeed, 30% of KM cells continued to missegregate chromo-somes compared with 10% in Kras tumors (Figures 5C and
5D), suggesting that Mad2 overexpression increases CIN prior
to tumorigenesis and during tumor cell expansion.
Mad2 Overexpression Facilitates Oncogene
Independence
To assess the effect of Mad2-induced CIN on tumor phenotype,
we analyzed tumor progression and histopathological features ofCell Reports 15, 2679–2691, June 21, 2016 2685
primary tumors. Despite the prolonged tumor onset, K and
KM cohorts displayed no differences in overall tumor growth
(Figure S5G) and developed similar histopathological subtypes
(Figure S5C). The tumor spectrum included mostly solid or solid-
papillary carcinomas (88%) that displayed a high number of HA-
Mad2-positive cells. A minor fraction of tumors was categorized
as tubulo-alveolar carcinomasandepithelial tomesenchymal tran-
sition (EMT) phenotype carcinosarcomas (Rudmann et al., 2012)
and contained fewer HA-Mad2-positive cells (Figure S5C).
Although a low number of mice developed lung metastases, the
incidence was not altered by Mad2 overexpression (data not
shown). The absence of an additional Mad2 effect despite the
elevated CIN in the KM tumors suggested that tumorigenesis
had so far followed the strong lead of the driving oncogene.
Over the past years, it has been argued that the full potential of
CIN can only be seen under selective conditions (Chen et al.,
2012, 2015). Here, karyotype diversity can boost the adaptive
potential of a cell population and enhance its fitness. We there-
fore set out to investigate whether the increased aneuploidy in
Mad2-expressing tumors would reveal its potential when faced
with strong selective pressure such as that seen with oncogene
inactivation. Doxycycline was withdrawn in 48 K and 44 KM an-
imals, each of which harbored multiple mammary tumors. In the
K cohort, a total of 155 out of 166 tumors completely regressed
to a non-palpable state (93.4%), demonstrating that the majority
of epithelial cells remained dependent on Kras for maintenance
of the transformed state. Strikingly, in the KM cohort, 23 of 108
primary tumors (21.3%) showed no signs of shrinkage, and ma-
lignant growth continued in the absence of doxycycline (Figures
5E and 5F). Activation of the same oncogenic pathway has been
described as a possible mechanism of doxycycline indepen-
dence (Podsypanina et al., 2008). To exclude the possibility of
transgene re-expression, non-regressing tumors were analyzed
for Kras and Mad2 transgene expression. Whereas 27.3% of K
and 34.8% of KM tumors re-activated the transgenic system
(Figure S6A), around 70% of persisting tumors remained unac-
counted for. In addition, no mutations were found in the endog-
enous ras genes (data not shown). This finding suggests that
genetic heterogeneity most likely had led to the establishment
of oncogene-independent subclones, facilitating tumor persis-
tence after transgene de-induction.
Mad2 Overexpression Delays Her2-Induced Breast
Cancer
Her2 is one of the most common oncogenes overexpressed or
amplified in human breast cancer (Moody et al., 2002; San-
chez-Garcia et al., 2014; Stephens et al., 2012). To test whether
our findings for Kras-driven mammary tumorigenesis also apply
to other breast cancer drivers, we crossed Mad2 animals into
tetracycline-inducible Her2 mice (Moody et al., 2002). Her2
(H)-positive animals developed tumors with a shorter median
latency (93 days, n = 60) than the ones observed with Kras
(p < 0.0001). Similar to the Kras model, overexpression of
Mad2 in Her2 animals (HM) led to a significant delay in tumor
onset (138 days, n = 73) and a decrease in the overall tumor
load per animal (Figures 6A and 6B).
Histology 4 and 100 days following transgene induction re-
vealed that Her2-driven tumorigenesis largely mimicked the2686 Cell Reports 15, 2679–2691, June 21, 2016continuous proliferation observed in Kras animals. Elevated
Mad2 levels in this model resulted in an increase in pH3-positive
cells accompanied by a predominant localization of mitotic cells
to the acinar lumen (Figures 6C and 6D). The delayed tumor
onset observed in the Her2/Mad2 animals might therefore also
be a consequence of Mad2-induced mitotic arrest.
Unlike the KM model, in which ultimately all tumors were pos-
itive for exogenous Mad2, a minor fraction of tumors (18%) in the
Her2/Mad2 cohort completely downregulated Mad2 expression
(Figure S6B). The Her2 model further differed in the appearance
of copy number changes. Whereas strong differences were
found between K and KM, H and HM tumors showed similar
numbers of SCNAs (mean 2.30 versus 2.60), withMad2-positive
tumors tending toward increased numerical aneuploidy
compared with Her2 tumors (Figures 6E and 6F; Figure S6C).
H and HM tumor cells also displayed similar missegregation
rates in vitro (Figures 6G and 6H). The elevated number of
SCNAs seen inHer2 tumors is in line with findings of centrosome
abnormalities and increased aneuploidy inMMTV-Her2-induced
murine breast cancer (Montagna et al., 2002). It is possible that
tumorigenesis can only proceed below a certain CIN threshold
(Jamal-Hanjani et al., 2015; Silk et al., 2013), restricting Mad2’s
effect to increase SCNAs on Her2 mammary tumors.
These results prompted us to investigate whether tumor
regression after transgenede-inductionwasaffected in these an-
imals. As seen previously with this model (Moody et al., 2002), of
174 Her2-positive tumors, only two tumors failed to fully regress
after doxycyclinewithdrawal (1.15%; Figure 6I). In theHMcohort,
a higher number of persistent tumors was detected, with 12 of
144 HM tumors not fully regressing upon inactivation of Her2
andMad2 (8.33%; Figure 6I). Strikingly, 50%of HMnon-regress-
ing tumors re-expressed the oncogene (Figure S6D), suggesting
that elevated Mad2 levels in the other 50% of Her2 primary tu-
mors also offered a selective benefit to enable the escape from
oncogene dependence. The presence of persistent tumors in
theHMmodelwasprobably not only a result of the induced aneu-
ploidy, given that similar levels of SCNAswere also present in the
H tumors that fully regressed. It is possible that tumor cells
require a certain time for the acquired CIN to generate and select
fitter tumor subclones. Whereas Her2 tumors arose very early
(93 days), Her2/Mad2 tumors needed a longer time to develop
(138 days), allowing sufficient time for the chromosome misse-
gregations to create oncogene-independent subclones. We
speculate that the biological context established by the initiating
oncogenic drivers as well as the mutational processes at work
thereafter are additional determinants of the genetic adaptation.
DISCUSSION
The consequence of chromosome instability on tumor deve-
lopment continues to stand at the center of a scientific debate.
Depending on genetic- and tissue-specific contexts, CIN-asso-
ciated gene de-regulations promote, suppress, or have no effect
on spontaneous tumorigenesis (Janssen and Medema, 2013;
Zasadil et al., 2013).
The overexpression of Mad2 is a frequent event in human can-
cers that has been modeled both in vitro and in vivo. The induc-
tion ofMad2 in adult mouse tissues leads to CIN, tumor initiation
Figure 6. Elevated Levels of Mad2 Delay Her2-Driven Breast Tumorigenesis without Affecting Aneuploidy
(A) Tumor-free survival after doxycycline administration (Her2, n = 60; Her2/Mad2, n = 73); Mantel-Cox test, p < 0.0001.
(B) Number of tumors per animal; Mann-Whitney test, p = 0.0062.
(C) Representative images of phospho-Histone 3 staining of mammary glands at 4 and 100 days on doxycycline. Scale bar, 50 mm.
(D) Quantification of pH3-positive cells per acinus at 4 days on doxycycline. Points represent single acinar measurements (CTRL, n = 6; H, n = 3; HM, n = 4);
Kruskal-Wallis test, p < 0.0001; Dunn’s multiple comparisons test.
(E) Average SCNAs in H and HM tumors; Fisher’s exact test, p = 1.
(F) Percentage of primary tumors of Her2 (left) and Her2/Mad2 cohort (right) containing specific structural variants per individual chromosome.
(G) Percentage of mitotic errors per tumor (H, n = 5; HM, n = 4); Mann-Whitney test, p = 0.125.
(H) Representative images showing misaligned chromosomes (arrows) in H and HM tumor cells in vitro (H2B-GFP, green). Scale bar, 20 mm.
(I) Status of tumor regression in H and HM cohort 2 months after doxycycline withdrawal.
**p < 0.01, ****p < 0.0001. See also Figure S6.(Sotillo et al., 2007), and acceleration of KrasG12D-driven lung
cancer (Sotillo et al., 2010). In this study, we extend this analysis
and show that elevated levels of Mad2 in the mammary gland
cause a delay in both KrasG12D- and Her2-induced breast can-
cer. The different outcomes upon Mad2 overexpression in the
lung versus the mammary gland might be due to tissue-specific
differences in cell homeostasis and signaling. The lung is one of
the tissues with the highest incidence of spontaneous tumor for-
mation in mouse models of CIN, suggesting that lung cells are
specially sensitive to aneuploidy (Duijf and Benezra, 2013). Alter-
natively, expression levels of the reverse tetracycline-controlled
transactivator (rtTA) driven by the lung-specific promoter (CCSP)
could differ from the mammary-specific MMTV promoter, mak-
ing it difficult to compare both models.
Murine breast cancer models allow multi-sampling of mam-
mary glands during tumor development from the same animal.
Taking advantage of this, we follow the transgenic effect in indi-
vidual animals and demonstrate that early Mad2 overexpressionin mammary cells in vivo leads to strong mitotic arrest and
increased cell death. Moreover, time-lapse imaging of mammary
spheroid cultures showed that prolonged mitotic arrest results in
apical extrusion and cell degradation inside the lumen. Apical
cell shedding is a common mechanism in epithelia to eliminate
defective cells (Denning et al., 2012; Rosenblatt et al., 2001).
Both the mitotic arrest and the higher mitotic error rate during
the first rounds of division might mark Mad2-expressing cells
as aberrant. It is also plausible that cells ultimately undergo anoi-
kis because of delamination (Gilmore, 2005). The signaling
pathway responsible for mitotic cell death is still unclear; how-
ever, it is possible that Myc contributes to apoptosis after pro-
longed checkpoint activation, as suggested recently (Topham
et al., 2015).
Strikingly, not all cells expressing Mad2 die. A small percent-
age of cells is able to overcome the arrest and complete cell di-
vision inside the epithelial layer. In all KM and the majority of HM
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leading to the formation of Mad2-positive tumors. The time and
route to steady state, however, vary among individuals. When
Mad2 expression strongly outweighs Kras (subgroup A), animals
show a substantial reduction of Mad2-expressing cells over
time. In subgroup B, where initial Kras and Mad2 levels are
high, mammary glands can maintain or even increase the num-
ber of Mad2-expressing cells. In subgroup C, a reduction of
Mad2 levels occurs, whereas Kras increases its expression.
The different phenotypes depend on a tight balance between
oncogenic andMad2 signaling. Pro-survival signals downstream
of Kras (Pylayeva-Gupta et al., 2011) and Her2 (Moasser, 2007)
as well as supporting signals from the microenvironment (Radi-
sky, 2012) might thereby promote cell cycle progression.
Considering that Mad2 increases karyotype instability, it is
possible that CIN-induced genetic changes might also take
part in the detrimental effect of early Mad2 expression and
contribute to overcoming checkpoint arrest or even subse-
quently support tumor initiation. Models combining chromo-
some missegregation with the process of negative selection
and tolerance, as seen in the presented mouse models, are
therefore good approximations to mimic human tumor growth
(Valind et al., 2013).
An increased occurrence of karyotype aberrations because of
Mad2 overexpression was primarily seen in KrasG12D-driven
mammary tumors. Mad2-positive tumors markedly outweigh
the solely KrasG12D-expressing counterparts in the genomic vari-
ance between cells as well as the number and complexity of
chromosomal rearrangements. Interestingly, Mad2 did not
further increase the high number of structural variants observed
inHer2mammary tumors but caused a slight trend toward whole
chromosome gains and losses. Her2 has been shown to cause
centrosomal defects and, thus, by itself, interferes with chromo-
some segregation (Montagna et al., 2002). The fact that
Mad2 did not significantly contribute to additional karyotype
complexity in the aneuploid Her2 tumors supports the hypothe-
sis that a certain threshold of CIN is permissive for tumor devel-
opment (Jamal-Hanjani et al., 2015; Laughney et al., 2015; Silk
et al., 2013). An alternative theory suggests that the genetic
setting shapes initial CIN and aneuploidy tolerance, which, after
rounds of negative selection, balances into an optimized equilib-
rium at a specific aneuploidy index (Laughney et al., 2015; Valind
et al., 2013).
Karyotypic heterogeneity can confer genetic flexibility and, in
turn, increase the adaptability of a tumor cell population. Here
we present in vivo evidence that Mad2-induced mitotic aberra-
tions enhance the generation of oncogene-independent tumor
subclones in breast cancer. Upon silencing of the driving onco-
gene, previously Mad2-expressing animals showed a higher
percentage of non-regressing tumors in the K and H models.
It is startling, however, that, despite the high number of struc-
tural variants in both H and HM tumors, the number of non-re-
gressing tumors is much lower than in KM while having similar
CIN levels. It may be that, given distinct initiating oncogenes,
differing grades of genomic instability are necessary for an
oncogene-independent subclonal population to arise. Alterna-
tively, the stochastic appearance of fitness-improving chromo-
somal changes depends on the time a tumor population has to
establish and expand itself. Multi-region sequencing and2688 Cell Reports 15, 2679–2691, June 21, 2016genomic profiling studies have verified that, although tumor
growth originates from early driver mutations, fitness-con-
tributing private alterations arise continuously during tumor
development (Sottoriva et al., 2015). Therefore, both genetic
instability-driving mechanisms and the time for tumor evolution
might contribute to the generation of oncogene-independent
cells. A previously reported MYC-induced breast cancer model
supports this argument.Myc-induced mammary tumors appear
at a very long latency compared with Kras and Her2 and are
associated with a strong CIN phenotype (McCormack et al.,
1998). Interestingly, incomplete regression following Myc inac-
tivation is observed in 60% of tumors (Leung et al., 2012),
whereas simultaneous overexpression of Mad2 in these ani-
mals results in a further increase of tumor persistence by
30% (M.M., unpublished data). The effect of transient Mad2
expression on the incidence of oncogene-independent tumors
is therefore discernable in three different oncogenic settings,
even if the overall adaptive capacity might depend on the initi-
ating oncogene.
Taken together, it is becoming clear why the effect of CIN on
tumor progression only becomes evident through strong selec-
tive pressures. Under such circumstances, the wide distribution
of karyotypes promotes gross adaptive leaps (Chen et al., 2012,
2015; Endesfelder et al., 2014). Therefore, it is not surprising that
CIN is found to be associated with poor prognosis and contrib-
utes to multidrug resistance (Lee et al., 2011; Zasadil et al.,
2013). Their predominant role as evolutionary drivers makes
CIN genes important predictive biomarkers in cancer (Carter
et al., 2006; Habermann et al., 2009). Further studies aiming at
understanding the contribution of individual CIN genes to onco-
gene independence will extend our understanding of intratu-
moral heterogeneity and tumor evolution. Considering the low
incidence of oncogene-independent tumors in some oncogenic
mousemodels, the combination with CINmodels might facilitate
the identification of escape mechanisms from targeted thera-
pies. The link between karyotypic and mutational changes
further complicates the understanding of tumor evolution (Shelt-
zer et al., 2011). The role and effect of CIN-induced genetic
changes has still to be determined and is likely to be an important
component during tumorigenesis and acquisition of therapeutic
resistance.
EXPERIMENTAL PROCEDURES
Animal Husbandry
Animals were of mixed background (mainly Friend virus B [FVB]) with a hetero-
zygous genotype: MMTV-rtTA (Gunther et al., 2002), TetO-KrasG12D (Fisher
et al., 2001), TetO-rat-Her2 (Moody et al., 2002), HA-tagged-TetO-Mad2
(Sotillo et al., 2007), and H2B-GFP (Hadjantonakis and Papaioannou, 2004).
ColA1-HA-Mad2 animals were included in the in vitro experiments (Supple-
mental Experimental Procedures). Breeding and experimentation was per-
formed at the European Molecular Biology Laboratory (EMBL) Monterotondo,
with ethical approval from the EMBL animal welfare and ethical review body
and in accordance with current Italian legislation (Art. 9; January 27, 1992;
no. 116) licensed by the Italian health ministry (Decree no. 233/2011-B). For
animal experimentation, see the Supplemental Experimental Procedures.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry was performed according to Sotillo et al. (2007). For
antibody details, see the Supplemental Experimental Procedures.
3D Organotypic Assays
Mammary glands were harvested from 8- to 9-week-old female mice and pre-
pared and stained according to published records (Jechlinger et al., 2009). The
following primary antibodies were used: HA (1:,1000, Covance, MMS-101R),
cleaved Caspase3 (1:200, Cell Signaling Technology, 9661S), LaminB1
(1:500, Abcam, 16048), a-Tubulin (1:500, Sigma, F2168), and Aurora B
(1:150, BD Biosciences, 611082). Imaging of fixed samples was performed
on a Leica TCS SP5/SP8 confocal microscope and time-lapse imaging during
20 hr on an inverted spinning disk confocal microscope (PerkinElmer Ultra-
view-Vox): 0.3-mm optical sectioning across a 35-mm stack, 5 frames/hr.
Volocity version 6.2 (Improvision, PerkinElmer) served for image acquisition
and analysis.
Tumor Cell Culture
Harvested tumors were digested with 150 U/ml Collagenase type 3 (Worthing-
ton, CLS3) and 20 mg/ml Liberase Blendzyme 2 (Roche, 11988425001) for
1 hr, washed with PBS, and dissociated with 0.25% Trypsin (Life Technolo-
gies, 25200056). Cells were cultured on 8-well chambered coverglass (Thermo
Scientific, 155411) in serum-free mammary epithelial basal medium (MEBM)
with supplements (Lonza, CC-3150) with 1 mg/ml doxycycline. Time-lapse im-
aging during 15 hr was performed on a confocal microscope (Leica TCS SP5):
2-mm optical sectioning across an 8-mm stack, 30 frames/hr. Volocity version
6.2 (Improvision, PerkinElmer) served for image analysis.
DNA Sequencing and Analysis
Genomic DNA was extracted from cells using the DNA blood mini kit
(QIAGEN). Library preparation and low-coverage sequencing were pursued
on an Illumina HiSeq 2500 platform (Illumina) using 50-base pair single-end
reads as described previously (Mardin et al., 2015). Reads were aligned to
the mm10 build of the mouse reference genome using Burrows-Wheeler
Aligner (BWA; version 0.7.10). Tumor coverage files were log2-normalized to
mouse genomic DNA derived from normal mammary tissue. Circular binary
segmentation (CBS; R package) was applied, and somatic copy number alter-
ations were categorized as follows. Whole chromosome gains/losses were
defined as chromosome-wide shifts in the segmentation of a chromosome,
whereas partial chromosome gains/losses entailed changes spanning at least
one-fifth of the chromosome. Focal amplifications and deletion encompassed
events smaller than this. When the number of copy number state switches on a
chromosome exceeded ten, they were called as gross chromosomal
rearrangements.
Statistical Analysis
Statistical analysis was carried out using Prism 6 (GraphPad). p values were as
follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scatterplots show
mean and SEM. Box-and-whisker plots show median interquartile ranges
plus minimum to maximum range. The number of animals is represented
with n. Control samples in vivo were animals containing the transgenes but
kept on a normal diet or animals lacking MMTV-rtTA feed with doxycycline
food. Non-induced cultures were considered controls in vitro.
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